By dividing 10,061 atherosclerotic patients with prior myocardial infarction and a high-sensitivity C-reactive protein (hs-CRP) ≥2 mg/L in 39 countries into a placebo group and three different doses of canakinumab, administered subcutaneously every three months. The gene discussed is CRP; the disease is myocardial infarction.